Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Commitments and Contingencies (Details Textual)

v3.20.2
Note 7 - Commitments and Contingencies (Details Textual)
3 Months Ended 9 Months Ended
Mar. 16, 2020
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sublease Income   $ 10,000 $ 31,000    
Operating Lease, Weighted Average Remaining Lease Term (Year)   2 years 8 months 12 days   2 years 8 months 12 days  
Operating Lease, Weighted Average Discount Rate, Percent   9.60%   9.60%  
Research and Development Expense, Total   $ 4,435,000 2,785,000 $ 10,971,000 $ 7,816,000
Houston Pharmaceuticals, Inc [Member]          
Related Party Transaction, Expenses from Transactions with Related Party   59,000 0 226,000 75,000
Houston Pharmaceuticals, Inc [Member] | Consulting Agreement on Licensed Molecules [Member]          
Other Commitments, Number of Agreements 2        
Other Commitment, Total $ 43,500        
Houston Pharmaceuticals, Inc [Member] | Agreement Providing Access to Laboratory Equipment [Member]          
Other Commitment, Total $ 15,000        
Other Commitments, Cancellation Period (Day) 60 days        
MD Anderson [Member]          
License Agreements Expense   61,000 60,000 183,000 180,000
Research and Development Expense, Total   $ 212,000 $ 177,000 $ 537,000 $ 366,000